Vimarsana
Biggest News Aggregation in the World

Comprehensive Centre News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Comprehensive Centre. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Comprehensive Centre Today - Breaking & Trending Today

Almirall: Nearly 80% of patients with moderate-to-severe atopic dermatitis maintained clear or almost-clear skin with lebrikizumab monthly maintenance dosing at two years -October 20, 2023 at 06:46 am EDT - Vimarsana News

Almirall: Nearly 80% of patients with moderate-to-severe atopic dermatitis maintained clear or almost-clear skin with lebrikizumab monthly maintenance dosing at two years -October 20, 2023 at 06:46 am EDT

First readout of two-year data from long-term extension study ...

Celebrity Pragathi Rishab Shetty Inaugurates Comprehensive Centre for Pediatric Care at KMC - Vimarsana News

Celebrity Pragathi Rishab Shetty Inaugurates Comprehensive Centre for Pediatric Care at KMC

Renowned Sandalwood Celebrity Artist Mrs Pragathi Rishab Shetty Inaugurates Comprehensive Centre for Pediatric Care at KMC Hospital, Dr B R Ambedkar

Almirall: The New England Journal of Medicine (NEJM) and the British Journal of Dermatology (BJD) publish Ph3 data evaluating lebrikizumab efficacy and safety in moderate-to-severe atopic dermatitis - Vimarsana News

Almirall: The New England Journal of Medicine (NEJM) and the British Journal of Dermatology (BJD) publish Ph3 data evaluating lebrikizumab efficacy and safety in moderate-to-severe atopic dermatitis

Almirall, S.A. (ALM), a global biopharmaceutical company focused on medical dermatology, announced today the publication of Week 16 and Week 52 results of ADvocate1 and ADvocate2 by the New England Journal of Medicine (NEJM) and the British Journal of Dermatology (BJD), respectively. ADvocate1 and ADvocate2 are two ...

Majority of Patients Treated with Lebrikizumab Achieved Skin Clearance in Pivotal Phase 3 Atopic Dermatitis Studies - Vimarsana News

Majority of Patients Treated with Lebrikizumab Achieved Skin Clearance in Pivotal Phase 3 Atopic Dermatitis Studies

More than 50 percent of patients with moderate-to-severe atopic dermatitis (AD) experienced at least 75 percent reduction in disease severity (EASI-75*) at 16 weeks when receiving lebrikizumab monotherapy in the ADvocate program, Almirall S.A. (BME: ALM) announced today at the American Academy of Dermatology (AAD) ...

Atopic Dermatitis skin clearance with new therapy - Vimarsana News

Atopic Dermatitis skin clearance with new therapy

More than 50 percent of patients with moderate-to-severe atopic dermatitis (AD) experienced at least 75 percent reduction in disease severity (EASI-75*)